Life-Saving CAE Air1 Ventilator Receives Health Canada Certification

CAE Air1 ventilator has been certified by Health Canada. The news was announced today by CAE.

CAE Air1 ventilator is made-in-Canada ventilator is destined for hospitals across the country where it will be used in the fight against COVID-19.

Certification comes two months after CAE signed a contract with the Government of Canada to manufacture and supply 10,000 ventilators.

“Since the beginning of the pandemic, CAE was the first to receive certification from Health Canada for an entirely new ventilator. It was created and manufactured in Canada, and we are proud that it will help save lives in the fight against COVID-19,” said Marc Parent, CAE’s President and CEO. “The agility shown by CAE in designing and succeeding to have the CAE Air1 ventilator certified in a fraction of the usual time is a testament to the strength of CAE’s innovation, engineering talent, and advanced manufacturing capabilities. I am proud of our team for rising to this humanitarian challenge and strengthening Canada’s self-sufficiency in the medical field during these unprecedented times.”

CAE will now start shipping hundreds of CAE Air1 ventilators to the Government of Canada every week. The CAE Air1 ventilator can deliver pressure control, volume control and pressure support ventilation using room air or pressured oxygen. It uses an intuitive, simple touchscreen interface and is bundled with on-demand ventilator training, adaptive e-learning modules related to COVID-19 patient management, and 24/7 customer support. It will support Intensive Care Units patients treated for COVID-19.

“CAE, one of Canada’s leading aerospace firms, stepped up early on with their commitment to produce a made-in-Canada ventilator design that will help save the lives of COVID-19 patients battling the disease. Today’s announcement is a testament to CAE’s agility and innovative capability. I am glad that we were able to support CAE in accelerating the design and manufacturing of CAE Air1 ventilator that is now ready to be used by our frontline healthcare workers,” said the Honourable Navdeep Bains, Canada’s Minister of Innovation, Science and Industry.

SourceCAE

Hot this week

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.